SRDX (Surmodics) LT-Debt-to-Total-Asset: 0.19 (As of Jun. 2025)

What is Surmodics LT-Debt-to-Total-Asset?

Surmodics SRDX -0.01% 51 LT-Debt-to-Total-Asset is 0.19 as of Jun. 2025. GuruFocus rates SRDX with a GF Score™ of 51/100 and a GF Value™ of $32.10. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Surmodics's long-term debt to total assests ratio for the quarter that ended in Jun. 2025 was 0.19.

Surmodics's long-term debt to total assets ratio increased from Jun. 2024 (0.18) to Jun. 2025 (0.19). It may suggest that Surmodics is progressively becoming more dependent on debt to grow their business.

Surmodics (NAS:SRDX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Surmodics LT-Debt-to-Total-Asset Related Terms

Surmodics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Surmodics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surmodics LT-Debt-to-Total-Asset Chart

Surmodics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.17

0.18

Surmodics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.18	0.18	0.20	0.20	0.19

51GF Score

Surmodics Inc SRDX

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Surmodics LT-Debt-to-Total-Asset Calculation

Surmodics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (A: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2024 )	/	Total Assets (A: Sep. 2024 )
	=	32.202	/	178.562
	=	0.18

Surmodics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (Q: Jun. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2025 )	/	Total Assets (Q: Jun. 2025 )
	=	31.558	/	169.822
	=	0.19

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.19 mean?

Surmodics (SRDX) has a LT-Debt-to-Total-Asset of 0.19 as of Jun. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Surmodics and its competitors.

Is Surmodics' LT-Debt-to-Total-Asset too high?

Surmodics' current LT-Debt-to-Total-Asset is 0.19. Overall, Surmodics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.

How does Surmodics' LT-Debt-to-Total-Asset compare to CBLL and OFIX?

Surmodics' LT-Debt-to-Total-Asset of 0.19 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Surmodics and its competitors. Surmodics's current LT-Debt-to-Total-Asset is 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Surmodics stock overvalued right now?

Surmodics (SRDX) has a current LT-Debt-to-Total-Asset of 0.19. The stock's GF Value™ is $32.10, compared to a current price of $42.98 — trading 33.9% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.19. Surmodics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Surmodics (SRDX), the current LT-Debt-to-Total-Asset is 0.19 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Surmodics (SRDX) Overvalued in 2026?

Based on GuruFocus' analysis, Surmodics stock appears to be overvalued. The current stock price of $42.98 is trading 33.9% above its estimated GF Value™ of $32.10.

Key valuation signals for SRDX:

LT-Debt-to-Total-Asset: 0.19
GF Value™: $32.10 vs. price of $42.98 (33.9% above fair value)
GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the SRDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Surmodics Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies CBLL OFIX LAB TCMD AVNS NPCE PACB BVS CTKB VREX ABT BSX SYK MDT XTER:SHL EW SZSE:300760 XAMS:PHIA STE DXCM

Address 9924 West 74th Street, Eden Prairie, MN, USA, 55344

Website https://www.surmodics.com

Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.

51GF Score

Get the complete analysis for SRDX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.98

Price

$32.10

GF Value

View SRDX Analysis

See LT-Debt-to-Total-Asset data for all stocks →